Tofersen in the treatment of SOD1 ALS — a two-year experience from the Polish Early Access Program
Neurologia i Neurochirurgia Polska · 16.11.2026
DOI: 10.5603/pjnns.113009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurologia i Neurochirurgia Polska, online erschienen am 16.11.2026. Verfasst von Magdalena Kuźma-Kozakiewicz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
Abstract (Originalsprache)
Introduction
The use of tofersen, an antisense oligonucleotide against SOD1, has been recommended for the treatment of SOD1–ALS by current European guidelines. Before full approval by national health funding agencies, patients received tofersen through the Early Access Program (EAP) and/or as rescue therapy. Aim of the study. The aim of the study was to prospectively analyze clinical outcomes and neurofilament light chain (NfL) concentration in patients participating in the EAP in Poland between October 2023 and October 2025. Material and methods. Twenty patients with SOD1–ALS (11 with familial and 9 with sporadic ALS; male:female ratio, 2.2:1) were enrolled in the EAP. They carried 11 SOD1 pathological variants, the most frequent being L145S and K4E. As 1 patient withdrew after the first dose of treatment, data were collected from 19 individuals. The median age at disease onset was 49 years (33–69 years). Disease duration before treatment was 39 months (8–110 months), and the median age at initiation of tofersen treatment was 51 years (39–74 years). The analysis included demographic and genetic data, ALS functional rating scale–revised (ALSFRS- –R), ALS progression rate, forced vital capacity (FVC), adverse events, and NfL concentration in cerebrospinal fluid.
Results
The median duration of tofersen treatment was 16 months (7–24 months). ALSFRS–R stabilized or increased in 68% of cases. Median delta ALSFRS–R during the treatment period was 0/month. The overall median progression rate decreased significantly from 0.218/month before treatment to 0.145/month at the last assessment (p < 0.0001). The decrease was observed in all patients, including fast–progressing individuals with continuous functional decline, as well as those with the most benign disease course. Two patients developed respiratory insufficiency, while FVC did not deteriorate in the remaining subjects. NfL concentration decreased in all analyzed patients, with significant reductions after 9 and 14 months. Serious treatment–related adverse events (SAEs) occurred in 3 patients and resolved without clinical consequences in 2 individuals. Two patients died due to disease progression and/or exacerbation of a preexisting condition/SAE.
Conclusions
The long–term follow–up data support the clinical efficacy and acceptable safety profile of tofersen treatment and demonstrate a biomarker response reflecting reduced axonal injury in both slow– and fast–progressing SOD1–ALS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
- Department of Neurology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland.
- Department of Neurology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland. justyna.zielinska@pinmswia.gov.pl.
- Department of Neurology, Medical College of Rzeszow University, Rzeszow, Poland.
- Centre for Innovative Medical Education, Jagiellonian University Medical College, Krakow, Poland.
- Department of Neurology, J. Dietl Specialist Hospital in Krakow, Krakow, Poland.
ORCID-Profile: Magdalena Kuźma-Kozakiewicz, Małgorzata Dorobek, Anna Gruszczak, Justyna Zielińska-Turek, Halina Bartosik-Psujek, Tomasz Garbacz, Kamila Żur-Wyrozumska, Dariusz M Koziorowski, Justyna Dutkiewicz, Ewa M Krzyżanowska, Błażej Początek, Agnieszka Migacz, Magdalena A Koszewicz, Jakub Ubysz, Krzysztof Szabat, Katarzyna Tomicka, Sebastian Student, Anetta Lasek-Bal
Zitieren
APA
Kuźma-Kozakiewicz, M., Dorobek, M., Gruszczak, A., Zielińska-Turek, J., Bartosik-Psujek, H., Garbacz, T., Żur-Wyrozumska, K., Koziorowski, D. M., Dutkiewicz, J., Krzyżanowska, E. M., Początek, B., Migacz, A., Koszewicz, M. A., Ubysz, J., Szabat, K., Tomicka, K., Student, S., & Lasek-Bal, A. (2026). Tofersen in the treatment of SOD1 ALS — a two-year experience from the Polish Early Access Program. Neurologia i Neurochirurgia Polska. https://doi.org/10.5603/pjnns.113009
Vancouver
Kuźma-Kozakiewicz M, Dorobek M, Gruszczak A, Zielińska-Turek J, Bartosik-Psujek H, Garbacz T, et al. Tofersen in the treatment of SOD1 ALS — a two-year experience from the Polish Early Access Program. Neurologia i Neurochirurgia Polska. 2026. doi:10.5603/pjnns.113009
BibTeX
@article{KumaKozakiewicz2026,
author = {Kuźma-Kozakiewicz, Magdalena and Dorobek, Małgorzata and Gruszczak, Anna and Zielińska-Turek, Justyna and Bartosik-Psujek, Halina and Garbacz, Tomasz and Żur-Wyrozumska, Kamila and Koziorowski, Dariusz M and Dutkiewicz, Justyna and Krzyżanowska, Ewa M and Początek, Błażej and Migacz, Agnieszka and Koszewicz, Magdalena A and Ubysz, Jakub and Szabat, Krzysztof and Tomicka, Katarzyna and Student, Sebastian and Lasek-Bal, Anetta},
title = {Tofersen in the treatment of SOD1 ALS — a two-year experience from the Polish Early Access Program},
journal = {Neurologia i Neurochirurgia Polska},
year = {2026},
doi = {10.5603/pjnns.113009}
}
EUVIMED